Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
140,800
Employees140,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
140,800
Employees140,800

JNJ Key Statistics

Market cap
615.41B
Market cap615.41B
Price-Earnings ratio
28.97
Price-Earnings ratio28.97
Dividend yield
2.10%
Dividend yield2.10%
Average volume
8.15M
Average volume8.15M
High today
$256.29
High today$256.29
Low today
$251.21
Low today$251.21
Open price
$252.61
Open price$252.61
Volume
8.62M
Volume8.62M
52 Week high
$269.43
52 Week high$269.43
52 Week low
$164.23
52 Week low$164.23

Stock Snapshot

With a market cap of 615.41B, Johnson & Johnson(JNJ) trades at $255.50. The stock has a price-to-earnings ratio of 28.97 and currently yields dividends of 2.10%.

As of 2026-07-22, Johnson & Johnson(JNJ) stock has fluctuated between $251.21 and $256.29. The current price stands at $255.50, placing the stock +1.7% above today's low and -0.3% off the high.

The Johnson & Johnson(JNJ)'s current trading volume is 8.62M, compared to an average daily volume of 8.15M.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $269.43 and a 52-week low of $164.23.

In the last year, Johnson & Johnson(JNJ) shares hit a 52-week high of $269.43 and a 52-week low of $164.23.

JNJ News

Reuters 12m
US judge casts doubt on 69,000 cases alleging J&J talc caused cancer - Reuters

...

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer - Reuters
Nasdaq 1h
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?

Key Points Vanguard Health Care ETF offers a lower expense ratio and higher dividend yield than Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has co...

As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?
Benzinga 4h
FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System

The marketing clearance encompasses multiple general surgery procedures. The medical technology giant will initiate a commercial rollout with select U.S. facil...

FDA Approves Johnson & Johnson Table-Integrated OTTAVA Robotic Surgery System

Analyst ratings

73%

of 26 ratings
Buy
73.1%
Hold
23.1%
Sell
3.8%

More JNJ News

TipRanks 6h
Johnson & Johnson Stock Rises as Robotic Surgery Device Is Approved

Shares of Johnson & Johnson (JNJ) are marching higher after the healthcare company’s robotic surgery device was approved by the U.S. Food and Drug Administratio...

Nasdaq 8h
Johnson & Johnson is Attracting Investor Attention: Here is What You Should Know

Johnson & Johnson (JNJ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might aff...

Johnson & Johnson is Attracting Investor Attention: Here is What You Should Know
Seeking Alpha 8h
J&J wins FDA nod for Ottava surgical robot

Johnson & Johnson (JNJ) on Wednesday announced that the FDA granted its De Novo authorization for the company’s soft tissue robotic system, Ottava, to handle mu...

J&J wins FDA nod for Ottava surgical robot
TipRanks 10h
Johnson & Johnson receives FDA Marketing Authorization in U.S. for OTTAVA

Johnson & Johnson announced that the U.S. Food and Drug Administration, FDA, has granted De Novo authorization for the OTTAVA Robotic Surgical System. The syste...

Simply Wall St 1d
Johnson & Johnson Stock Looks Fairly Valued With Cash Flow Upside

Johnson & Johnson stock has delivered a 66.6% gain over the past 5 years, yet current checks flag a mixed picture on value, with the Discounted Cash Flow (DCF)...

Johnson & Johnson Stock Looks Fairly Valued With Cash Flow Upside
24/7 Wall St. 1d
Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories By Vandita Jadeja Published Jul 21, 11:00AM EDT Quick Read JNJ's 64-y...

Johnson & Johnson vs Abbott Laboratories: Two Healthcare Giants on Opposite Trajectories
24/7 Wall St. 2d
Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD

Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD By Thomas Richmond Published Jul 20, 1:57PM EDT Quick Read Cramer calls B...

Jim Cramer: Alibaba Is “Still the Best Way to Play China” Despite Being Down 18% YTD

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.